| Today’s Big NewsMay 13, 2025 |
| By Nick Paul Taylor GSK has stopped development of anti-TIGIT antibody belrestotug. The Big Pharma and its partner iTeos Therapeutics took the action after an assessment of the effect on progression-free survival fell short of expectations. |
|
|
|
By James Waldron Azafaros has secured 132 million euros ($147 million) in series B funds that the Dutch biotech will use to push its brain disease drug through two late-stage trials. |
By James Waldron Only five months after Galapagos announced it would split in two, the cell-therapy-focused biotech is already having second thoughts. |
Sponsored by Medrio Medrio CEO Nicole Latimer discusses strategiesthe company’s mission to streamline clinical trials, embrace meaningful innovation and support life sciences organizations from startup to FDA approval. |
|
Explore our end-to-end, integrated drug substance and drug product capabilities across biologic modalities. This presentation highlights recent expansions at the Stein, Switzerland site including the large-scale manufacturing expansion, dedicated to biologics filling in vials as liquid/lyo, PFS and cartridges, as well as ADC manufacturing services. +(1)+(1).png)
|
|
By James Waldron Atara Biotherapeutics continues to salami slice its head count, this time laying off 30% of what remains of its workforce. |
By James Waldron Leap Therapeutics is laying off half of its staff as it narrows the focus of its lead cancer drug against the backdrop of a “difficult market environment," its CEO explained. |
By Nick Paul Taylor An appeals court has opened another chapter in the long-running CRISPR patent saga. Three years after a patent body ruled in favor of the teams behind Editas Medicine’s intellectual property, an appeals court has found fault with the decision and sent the case back for reassessment. |
By Gabrielle Masson Cancer company Erasca is seeking a partner for its most advanced asset, a pan-RAF inhibitor being studied in a phase 3 melanoma study and a phase 1b solid tumor trial. The company is taking this direction in hopes of adding another year to its cash runway. |
By Gabrielle Masson Stylus Medicine is unsheathing, penning a mission to develop next-gen in vivo genetic medicines with $85 million in hand, cofounder Patrick Hsu, Ph.D., told Fierce Biotech. |
By Darren Incorvaia The founder and former leader of Inhibikase Therapeutics is blazing a new biotech trail in an effort to get a beleaguered Parkinson’s candidate over the finish line. |
By Darren Incorvaia North Carolina-based CRO Fortrea is saying goodbye to its CEO. Thomas Pike is hitting the road effective May 13 and will be replaced in the interim by Peter Neupert, Fortrea’s lead independent director. |
By Angus Liu Bluebird bio shareholders have dragged their feet in tendering shares as part of the company's sale process, prompting buyers Carlyle and SK Capital to extend their offer once again. |
By Paige Minemyer UnitedHealth Group CEO Andrew Witty will step down from his role at the top of the company due to personal reasons, the healthcare giant announced Tuesday morning. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Angela Hwang reflects on her leap from nearly 30 years at Pfizer to leading a biotech startup—and the career lessons that continue to guide her leadership and commitment to developing diverse talent. |
|
|---|
|
|
Whitepaper Don’t delay your gene transfer trial’s start-up timeline by gaining the latest insights from WCG’s case study on the power of a seamless Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) review process. Sponsored by: WCG |
Whitepaper Learn how the SpyLock service can offer fast bispecific generation, reduce workload, and accelerate candidate selection. Sponsored by: Bio-Rad |
Whitepaper We interviewed 24 Medical Affairs leaders on the critical success factors for building a Best Practice Medical Affairs organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
+(2).png)
